Chemokine receptor antagonism as a new therapy for multiple sclerosis

Expert Opinion on Investigational Drugs

Volumn 9, Issue 5, 2000, Pages 1079-1097

  Ransohoff, R M ^a   Bacon, K B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chemokines; Demyelination; Inflammation; Leukocytes; Multiple sclerosis; Receptor antagonists

Indexed keywords

BETA INTERFERON; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; GLATIRAMER; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RECEPTOR BLOCKING AGENT; WO 9 44329; WO 9724325; WO 98 58033; WO 9802151; WO 9804554; WO 9806703; WO 9831364; WO 99 09984; WO 99 40061; WO 9907351; WO 9907678; WO 9925686; WO 9937617; WO 9937619; WO 9937651; WO 9940913; WO 9940914;

CLINICAL FEATURE; DEMYELINATION; DRUG STRUCTURE; EXTRAVASATION; HUMAN; INFLAMMATION; LEUKOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOLOGY; REVIEW;

EID: 0034098235     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.5.1079     Document Type: Review

References (119)